About Dante Labs
Dante Labs is a clinical genomics company that makes whole genome sequencing accessible to individuals and healthcare providers worldwide. Founded in 2016 and headquartered in New York City, the company has sequenced over 100,000 genomes and delivered more than 1.3 million clinical reports to customers in over 100 countries. Dante Labs sequences the entire genome—not just targeted gene panels—at 30X coverage with 99.98% accuracy in ISO 15189-accredited, CLIA-certified, and CAP-accredited laboratories in Europe and the United States. The company's approach addresses situations where standard genetic testing falls short: hereditary conditions that run in families, unexplained symptoms with no clear diagnosis, treatments that aren't working as expected, and proactive health planning. Each genome test generates over 200 physician-ready clinical reports organized by category, including cardiovascular, hereditary cancer, neurological, rare diseases, metabolic, pharmacogenomics, and autoimmune conditions. Results are classified to ACMG standards—the same framework used by major medical institutions—and are automatically updated as new variant-disease associations are discovered. The company also offers RNA profiling and oncology-specific genomic analysis. Dante Labs' mission is to make comprehensive genomic information clinically actionable, helping patients and physicians make informed decisions together. The company has documented clinical outcomes where its genomic data enabled diagnoses at NHS hospitals and changed treatment plans for conditions including Noonan Syndrome, RUNX1 deficiency, GLUT-1 epilepsy, and chemotherapy selection in breast cancer patients.
Mission & Story
Mission
Make whole genome sequencing clinically accessible—with results a physician can act on, at a cost that doesn't require institutional backing
Founding Story
Co-founded by Andrea Riposati in 2016 after seeing how long it took clinical genomics to reach the people who needed it most. Before Dante, Andrea launched 3D Printing at Amazon, built marketplace algorithms at Amazon Business, and consulted at Booz & Company. He holds an MBA from Harvard Business School and was on the teaching faculty at Harvard's Department of Economics. The company name reflects the founding intent—'Dante' after the Italian poet who made the complex comprehensible; 'Labs' for the clinical science that makes it possible.
Clinical Focus
Medical conditions and clinical areas addressed by Dante Labs.
Who It Serves
Milestones & Awards
Recent Milestones
Over 100,000 genomes sequenced. Documented clinical outcomes with NHS genetics teams. CEO Andrea Riposati presented at Italian Tech Week 2023. Recognition in Financial Times Top 25 European Fastest Growing Companies and Sole 24 Ore Growth Leaders.
Awards & Recognition
EY Entrepreneur of the Year 2019 (Andrea Riposati). Financial Times Top 25 European Fastest Growing Companies. Sole 24 Ore Growth Leaders. Forbes Technology Council member (Andrea Riposati).
Key Partnerships
Company Details
- Founded
- 2016
- Headquarters
- New York City, NY, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.